Zoryve (roflumilast) vs Wezlana (ustekinumab-auub)
Zoryve (roflumilast) vs Wezlana (ustekinumab-auub)
Zoryve (roflumilast) is a topical phosphodiesterase-4 (PDE4) inhibitor indicated for the treatment of plaque psoriasis in adults, applied directly to the skin to reduce inflammation and plaque formation. Wezlana (ustekinumab-auub), on the other hand, is a systemic biologic therapy, a human interleukin-12 and -23 antagonist, used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and other inflammatory conditions, administered via subcutaneous injection. When deciding between the two, patients should consider factors such as the severity of their condition, preference for topical versus injectable treatment, and their individual response and tolerance to these medications, all of which should be discussed with a healthcare provider.
Difference between Zoryve and Wezlana
Metric | Zoryve (roflumilast) | Wezlana (ustekinumab-auub) |
---|---|---|
Generic name | roflumilast | ustekinumab-auub |
Indications | Plaque psoriasis | Plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Mechanism of action | Phosphodiesterase-4 (PDE4) inhibitor | Interleukin-12 and -23 antagonist |
Brand names | Zoryve | Wezlana |
Administrative route | Topical | Subcutaneous injection |
Side effects | Diarrhea, headache, insomnia, nausea | Nasopharyngitis, headache, upper respiratory infections, fatigue |
Contraindications | Hypersensitivity to roflumilast or any component of the formulation | Hypersensitivity to ustekinumab or any component of the formulation |
Drug class | PDE4 inhibitor | Monoclonal antibody |
Manufacturer | Arcutis Biotherapeutics | Janssen Biotech, Inc. |
Efficacy
Zoryve (Roflumilast) Efficacy in Psoriasis
Zoryve, with the active ingredient roflumilast, is a phosphodiesterase 4 (PDE4) inhibitor indicated for the topical treatment of plaque psoriasis, including intertriginous areas. Roflumilast has demonstrated efficacy in reducing the symptoms of plaque psoriasis in clinical trials. Patients treated with Zoryve have shown significant improvements in the Psoriasis Area and Severity Index (PASI) scores, which is a measure of the severity of psoriasis plaques in terms of thickness, redness, and scaliness. The efficacy of Zoryve in improving the quality of life for patients with psoriasis has also been reported, with a notable reduction in itch and discomfort associated with the condition.
The clinical trials for Zoryve have included a diverse population of adult patients with chronic plaque psoriasis. In these studies, Zoryve was applied once daily to affected areas. The results indicated that a significant number of patients achieved clear or almost clear skin, as assessed by the Investigator's Global Assessment (IGA) score, which is another commonly used measure of treatment success in psoriasis. These outcomes suggest that Zoryve is an effective topical treatment option for individuals with plaque psoriasis seeking relief from their symptoms.
Wezlana (Ustekinumab-auub) Efficacy in Psoriasis
Wezlana, which contains the active substance ustekinumab-auub, is a biologic therapy approved for the treatment of moderate to severe plaque psoriasis. Ustekinumab is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines known to be involved in the inflammatory processes of psoriasis. The efficacy of Wezlana in treating psoriasis has been established through various clinical trials, where it has been shown to achieve significant improvements in PASI scores in a majority of patients.
Long-term studies of ustekinumab have demonstrated sustained efficacy and safety over several years of treatment, which is crucial for a chronic condition like psoriasis that requires ongoing management. The treatment with Wezlana has not only been associated with improvements in skin clearance but also with enhanced quality of life and reduction of psoriasis-related symptoms. Moreover, ustekinumab has been found to be beneficial for patients who have not responded adequately to conventional systemic therapies or who have contraindications to other systemic treatments. This makes Wezlana a valuable treatment option for a broad range of patients with psoriasis.
Regulatory Agency Approvals
Zoryve
Wezlana
Access Zoryve or Wezlana today
If Zoryve or Wezlana are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us